PSMA-targeted dendrimers: a patent evaluation (WO2012078534)

Bibliography

• Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-35
   PubMed Web of Science ®Google Scholar
• Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-30
   PubMed Web of Science ®Google Scholar
• Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11
   PubMed Web of Science ®Google Scholar
• Wright GL Jr, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28
   PubMedGoogle Scholar
• Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-8
   PubMed Web of Science ®Google Scholar
• Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000;43:150-7
   PubMed Web of Science ®Google Scholar
• Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011;108:9578-82
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5
   PubMed Web of Science ®Google Scholar
• Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34
   PubMed Web of Science ®Google Scholar
• Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8
   PubMed Web of Science ®Google Scholar
• Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81
   PubMed Web of Science ®Google Scholar
• Akhtar NH, Pail O, Saran A, et al. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012;2012:973820
   PubMedGoogle Scholar
• Osborne JR, Akhtar NH, Vallabhajosula S, et al. Prostate-specific membrane antigen-based imaging. Urol Oncol 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002;6:466-71
   PubMed Web of Science ®Google Scholar
• Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol 2002;6:742-8
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010;116:1075-83
   PubMed Web of Science ®Google Scholar
• Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Prac Urol 1996;3:216-25
   Google Scholar
• Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009;52:347-57
   PubMed Web of Science ®Google Scholar
• Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011;17:7645-53
   PubMed Web of Science ®Google Scholar
• Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53:1883-91
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5
   PubMed Web of Science ®Google Scholar
• Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Caner Res 2009;69:6932-40
   PubMed Web of Science ®Google Scholar
• Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008;51:7933-43
   PubMed Web of Science ®Google Scholar
• Banerjee SR, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J med Chem 2010;53:5333-41
   Google Scholar
• Hillier SM, Kern AM, Maresca KP, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011;52:1087-93
   PubMed Web of Science ®Google Scholar
• Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011;17:7645-53
   PubMed Web of Science ®Google Scholar
• Svenson S, Tomalia DA. Dendrimers in biomedical applications —reflections on the field. Adv. Drug Deliv. Rev 2005;57:2106-29
   PubMed Web of Science ®Google Scholar
• Gillies ER, Dy E, Frechet JM, et al. Biological evaluation of polyester dendrimer: poly(ethylene oxide) “bow-tie” hybrids with tunable molecular weight and architecture. Mol Pharm 2005;2:129-38
   PubMed Web of Science ®Google Scholar
• Lee CC, Gillies ER, Fox ME, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U. S. A 2006;103:16649-54
   PubMed Web of Science ®Google Scholar
• Barth RF, Adams DM, Soloway AH, et al. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem 1994;5:58-66
   PubMed Web of Science ®Google Scholar
• Patri AK, Myc A, Beals J, et al. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004;15:1174-81
   PubMed Web of Science ®Google Scholar